Table 1.
The main information and risk of bias assessment of the included RCTs.
| Author | Year | Age*I(n);C(n) | SDM | Interventions (usage) | Comparison (usage) | Duration | Risk of Bias Assessment (ROB) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RSG | AC | PB | DB | AB | RB | OB | Overall | |||||||
| Pan | 2021 | 54.57 ± 10.54(33); 56 ± 9.47(36) | N.A. | Metformin (0.5g tid)+ Jinlida granule (9g tid) |
Metformin (0.5g tid)+ placebo (9g tid) |
16 weeks | Low | Low | Low | Low | Low | Low | Unclear | Low |
| Lian | 2015 | 55.18 ± 9.13(92); 55.81 ± 9.93 (94) | N.A. | Metformin(0.5g bid)+ Jinlida granule (9g tid) | Metformin (0.5g bid) +placebo (9g tid) |
12 weeks | Low | Low | Low | Low | Low | Low | Unclear | Low |
| Zhao | 2017 | 51.76 ± 8.88(78); 49.44 ± 10.93(78) |
N.A. | Metformin(0.5g tid)+ Jinlida granule (9g tid) |
Metformin (0.5g tid)+ placebo (9g tid) |
12 weeks | Low | Low | Low | Low | Low | Unclear | Unclear | Low |
| Wang | 2016 | 54.28 ± 9.23(90); 54.71 ± 9.83(90) | N.A. | Metformin(1.5g/day)+ Jinlida granule (9g tid) |
Metformin(2g/day) | 12 weeks | Low | Unclear | High | High | Low | Unclear | Unclear | High |
| 2021 | 57.58 ± 2.13(50); 57.7 ± 2.24(50) | N.A. | Metformin(0.25g tid)+ Jinlida granule(9g tid) |
Metformin(0.25g tid) | 3month | Low | Unclear | High | High | Low | Unclear | Unclear | High | |
| Zhang | 2019 | 47.25 ± 5.17(61); 46.61 ± 5.08(61) | N.A. | Metformin(0.5g tid)+ Jinlida granule (9g tid) |
Metformin(0.5g tid) | 12 weeks | Low | Unclear | High | High | Low | Unclear | Unclear | High |
| Wu | 2019 | 45.14 ± 6.13(56); 46.32 ± 5.55(56) | QYD | Metformin(0.5g tid)+ Jinlida granule (9g tid) |
Metformin(0.5g tid) | 3month | Low | Unclear | High | High | Low | Unclear | Unclear | High |
| Liu | 2017 | 69.1 ± 8.2 (60); 68.6 ± 7.1 (60) | N.A. | Metformin(0.5g tid)+ Jinlida granule (9g tid) |
Metformin(0.5g tid) | 8 weeks& | Low | Unclear | High | High | Low | Unclear | Unclear | High |
| Li | 2017 | 72.96 ± 2.87(46); 72.16 ± 2.14(46) | QYD | Metformin(0.5g tid)+ Jinlida granule(9g tid) |
Metformin(0.5g tid) | 3month# | Low | Unclear | High | High | Low | Unclear | Unclear | High |
| Zhou | 2020 | 32.48 ± 2.28(39); 32.51 ± 2.25(39) | N.A. | Metformin(0.5g tid)+ Jinlida granule(9g tid) |
Metformin(0.5g tid) | 3month& | Unclear | Unclear | High | High | Low | Unclear | Unclear | High |
| Wang | 2020 | 50.57 ± 8.1(65); 47.89 ± 6.72(65) | N.A. | Metformin(0.5g tid)+ Jinlida granule(9g tid) |
Metformin(0.5g tid) | 12 weeks | Unclear | Unclear | High | High | Unclear | Unclear | Unclear | High |
| Liu | 2020 | 64.42 ± 5.31(40); 63.96 ± 5.42(40) | N.A. | Metformin(0.5g tid)+ Jinlida granule(9g tid) |
Metformin(0.5g tid) | 3month | Unclear | Unclear | High | High | Low | Unclear | Unclear | High |
| Zhang | 2019 | 62.4 ± 5.9(30); 62.1 ± 6.1(30) | N.A. | Metformin(≥1g/day)+ Jinlida granule(9g tid) |
Metformin(≥1g/day) | 8 weeks& | Unclear | Unclear | High | High | Low | Unclear | Unclear | High |
| Liu | 2018 | 48.26 ± 4.93(35); 47.14 ± 4.87(35) | N.A. | Metformin(0.5g bid)+ Jinlida granule (9g tid) |
Metformin(0.5g tid) | 8 weeks | Unclear | Unclear | High | High | Unclear | Unclear | Unclear | High |
| Wang | 2017 | 56 ± 13.5(55); 57 ± 12.1(55) |
N.A. | Metformin (0.5g tid)+ Jinlida granule (9g tid) |
Metformin (0.5g tid) | 60days | Unclear | Unclear | High | High | Low | Unclear | Unclear | High |
| Zheng | 2016 | 46 ± 4(74); 48 ± 5(74) | N.A. | Metformin(0.5-1g/day) +Jinlida granule((9g tid) |
Metformin(0.5-1g/day) | 3month | Unclear | Unclear | High | High | Low | Unclear | Unclear | High |
| Yue | 2016 | 40-63(30); 43-74(30) | N.A. | Metformin (N.A.)+ Jinlida granule (9g tid) |
Metformin (N.A.) | 16 weeks | Unclear | Unclear | High | High | Unclear | Unclear | Unclear | High |
| Guo | 2013 | 53.2 ± 9.4(44); 52.2 ± 9.5(44) | N.A. | Metformin (0.5g tid)+ Jinlida granule (9g tid) |
Metformin (0.5g tid) | 16 weeks | Unclear | Unclear | High | High | Low | Unclear | Unclear | High |
| Song | 2017 | 55.1 ± 12.4(30); 56 ± 11.4(30) |
N.A. | Metformin(0.5g tid)+ Jinlida granule(9g tid) |
Metformin(0.5g tid) | 3month | Low | Unclear | High | High | Low | Unclear | Unclear | High |
| Yuan | 2018 | 45 ± 6(66); 46 ± 4(66) | N.A. | Metformin (N.A.)+ Jinlida granule(9g tid) |
Metformin (N.A.) | 4month | Unclear | Unclear | High | High | Low | Unclear | Unclear | High |
| Tang | 2017 | 51.83 ± 12.61(35); 51.11 ± 11.44(35) | N.A. | Metformin(0.25g tid)+ Jinlida granule(9g tid) |
Metformin(0.25g tid) | 8 weeks | Unclear | Unclear | High | High | Low | Unclear | Unclear | High |
| Su | 2014 | 30-70 (30); 30-70 (30) | QYD+ blood- stasis |
Metformin (N.A.)+ Jinlida granule (9g tid) |
Metformin (N.A.) | 12 weeks | Unclear | Unclear | High | High | Low | Unclear | Unclear | High |
SDM, syndrome differentiation of traditional Chinese medicine; n, sample size; I, interventions; C:comparison; N.A., not available; RSG, random sequence generation; AC, allocation concealment; PB, performance bias; DB, detection bias; AB, attrition bias; RB, reporting bias; OB, other bias; *Mean ± standard deviation (year); bid: two times daily; tid: three times daily; #without outcome of PBG; &without outcome of HbA1c. QYD, qi-yin deficiency pattern.